Latest & greatest articles for lovastatin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lovastatin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lovastatin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lovastatin

1. Topical cholesterol/lovastatin for the treatment of porokeratosis: a pathogenesis-directed therapy. Full Text available with Trip Pro

Topical cholesterol/lovastatin for the treatment of porokeratosis: a pathogenesis-directed therapy. Porokeratosis is associated with mevalonate pathway gene mutations. Therapeutic options are few and often limited in efficacy.On the basis of preventing the accumulation of toxic metabolites while replenishing essential end-products, we studied the efficacy of topical lovastatin/cholesterol in different variants of porokeratosis.A series of 5 patients with disseminated superficial actinic (...) porokeratosis (DSAP,n=1), porokeratosis palmaris et plantaris disseminata (PPPD,n=2) and linear porokeratosis (LP,n=2) were enrolled. Patients were genotyped prior to initiation of therapy and then applied topical lovastatin/cholesterol twice daily to a unilateral defined treatment area for up to 3 months. Response was evaluated and patients were photographed every visit.Three patients had MVD mutations and 2 patients had PMVK mutations. Treatment with topical lovastatin/cholesterol (but not cholesterol

2019 Journal of American Academy of Dermatology

2. Lovastatin

Lovastatin Top results for lovastatin - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for lovastatin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

3. Use of Topical Glycolic Acid Plus a Lovastatin-Cholesterol Combination Cream for the Treatment of Autosomal Recessive Congenital Ichthyoses. Full Text available with Trip Pro

Use of Topical Glycolic Acid Plus a Lovastatin-Cholesterol Combination Cream for the Treatment of Autosomal Recessive Congenital Ichthyoses. Autosomal recessive congenital ichthyosis (ARCI) is a heterogeneous group of disorders caused by defects in signaling pathways involved in epidermal proliferation and differentiation, leading to a wide range of skin manifestations. Therapeutic options are limited and often unsatisfactory. Topical cholesterol and statin as a combined formulation has proven (...) successful in the treatment of patients with CHILD syndrome (congenital hemidysplasia ichthyosis and limb defects).To assess change in disease severity score after a 3-month therapeutic regimen consisting of a glycolic acid, 10% to 20%, cream and a combination cream of lovastatin, 2%, with cholesterol, 2%, in the treatment of ARCI.This case series of 15 patients with ARCI was conducted at the American University of Beirut, a referral center in the Middle East region for genodermatoses, between May 2017

2018 JAMA dermatology (Chicago, Ill.)

4. A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritis Full Text available with Trip Pro

A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritis 3-hydroxy-3-methylglutaryl coenzyme-A (HMG Co-A) reductase inhibitors (statins) are standard treatment for hyperlipidaemia. In addition to lipid-lowering abilities, statins exhibit multiple anti-inflammatory effects. The objectives of this study were to determine whether treatment of patients with RA with lovastatin decreased CRP or reduced disease (...) activity.We conducted a randomized double-blind placebo-controlled 12 week trial of lovastatin vs placebo in 64 RA patients with mild clinical disease activity but an elevated CRP. The primary efficacy end point was the reduction in mean log CRP. Secondary end points included disease activity, RF and anti-CCP antibody titres. Mechanistic end points included levels of serum cytokines. Safety was assessed; hepatic and muscle toxicities were of particular interest.Baseline features were similar between

2019 EvidenceUpdates

5. Lovastatin Reduces Stemness via Epigenetic Reprograming of BMP2 and GATA2 in Human Endometrium and Endometriosis Full Text available with Trip Pro

Lovastatin Reduces Stemness via Epigenetic Reprograming of BMP2 and GATA2 in Human Endometrium and Endometriosis The stem cell theory in the endometriosis provides an advanced avenue of targeting these cells as a novel therapy to eliminate endometriosis. In this regard, studies showed that lovastatin alters the cells from a stem-like state to more differentiated condition and reduces stemness. The aim of this study was to investigate whether lovastatin treatment could influence expression (...) and methylation patterns of genes regulating differentiation of endometrial mesenchymal stem cells (eMSCs) such as BMP2, GATA2 and RUNX2 as well as eMSCs markers.In this experimental investigation, MSCs were isolated from endometrial and endometriotic tissues and treated with lovastatin and decitabin. To investigate the osteogenic and adipogenic differentiation of eMSCs treated with the different concentration of lovastatin and decitabin, BMP2, RUNX2 and GATA2 expressions were measured by real-time polymerase

2016 Cell Journal (Yakhteh)

6. The Effect of Lovastatin Gel in the Treatment of Chronic Periodontitis

The Effect of Lovastatin Gel in the Treatment of Chronic Periodontitis The Effect of Lovastatin Gel in the Treatment of Chronic Periodontitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. The Effect (...) of Lovastatin Gel in the Treatment of Chronic Periodontitis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03178526 Recruitment Status : Completed First Posted : June 7, 2017 Last Update Posted : February 12, 2019 Sponsor: Islamic Azad University, Tehran Information provided by (Responsible Party

2017 Clinical Trials

7. Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis

Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Lovastatin (...) (NIAID) Collaborator: Autoimmunity Centers of Excellence Information provided by (Responsible Party): National Institute of Allergy and Infectious Diseases (NIAID) Study Details Study Description Go to Brief Summary: Rheumatoid arthritis (RA) is the most common inflammatory arthritis and a major health problem. The purpose of this study is to determine the safety and effectiveness of lovastatin for controlling inflammation in mildly active RA. Condition or disease Intervention/treatment Phase

2006 Clinical Trials

8. Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous Xanthomatosis

Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous Xanthomatosis Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous Xanthomatosis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous Xanthomatosis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00004346

1999 Clinical Trials

9. Lovastatin enhances the replication of the oncolytic adenovirus dl1520 and its antineoplastic activity against anaplastic thyroid carcinoma cells. Full Text available with Trip Pro

Lovastatin enhances the replication of the oncolytic adenovirus dl1520 and its antineoplastic activity against anaplastic thyroid carcinoma cells. Anaplastic thyroid carcinoma (ATC) is one of the most aggressive solid tumors and shows morphological features of a highly malignant, undifferentiated neoplasm. Patients with ATC have a poor prognosis with a mean survival time of 2-6 months; surgery, radiotherapy, and chemotherapy do not improve survival. Gene therapy approaches and oncolytic viruses (...) have been tested for the treatment of ATC. To enhance the antineoplastic effects of the oncolytic adenovirus dl1520 (Onyx-015), we treated ATC cells with lovastatin (3-hydroxy-methylglutaryl-CoA reductase inhibitor), a drug used for the treatment of hypercholesterolemia, which has previously been reported to exert growth-inhibitory and apoptotic activity on ATC cells. Lovastatin treatment significantly increased the effects of dl1520 against ATC cells. The replication of dl1520 in ATC cells

2007 Endocrinology

10. Lovastatin in X-linked adrenoleukodystrophy. Full Text available with Trip Pro

Lovastatin in X-linked adrenoleukodystrophy. 20089986 2010 01 28 2013 11 21 1533-4406 362 3 2010 Jan 21 The New England journal of medicine N. Engl. J. Med. Lovastatin in X-linked adrenoleukodystrophy. 276-7 10.1056/NEJMc0907735 Engelen Marc M Ofman Rob R Dijkgraaf Marcel G W MG Hijzen Michiel M van der Wardt Lucinda A LA van Geel Bjorn M BM de Visser Marianne M Wanders Ronald J A RJ Poll-The Bwee Tien BT Kemp Stephan S eng ISRCTN ISRCTN31565393 Comparative Study Letter Randomized Controlled (...) Trial United States N Engl J Med 0255562 0028-4793 0 Cholesterol, LDL 0 Fatty Acids 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors 9LHU78OQFD Lovastatin D42CQN6P36 hexacosanoic acid RK3VCW5Y1L lignoceric acid AIM IM Adrenoleukodystrophy blood drug therapy Cholesterol, LDL blood Cross-Over Studies Double-Blind Method Fatty Acids analysis blood Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use Lovastatin therapeutic use Pilot Projects 2010 1 22 6 0 2010 1 22 6 0 2010 1 29 6 0

2010 The New England journal of medicine Controlled trial quality: uncertain

11. Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. (Abstract)

Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. 12008177 2002 06 14 2018 11 30 0002-9149 89 10 2002 May 15 The American journal of cardiology Am. J. Cardiol. Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris (...) Comparative Study Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. United States Am J Cardiol 0207277 0002-9149 0 Cholesterol, HDL 0 Cholesterol, LDL 0 Heptanoic Acids 0 Hypolipidemic Agents 0 Pyrroles 0 Triglycerides 9007-41-4 C-Reactive Protein 9LHU78OQFD Lovastatin A0JWA85V8F Atorvastatin AIM IM Adolescent Adult Aged Aged, 80 and over Angina Pectoris blood complications drug therapy Atorvastatin C-Reactive Protein drug effects Cholesterol

2002 The American journal of cardiology Controlled trial quality: uncertain

12. Dose response, safety, and efficacy of an extended-release formulation of lovastatin in adults with hypercholesterolemia. (Abstract)

Dose response, safety, and efficacy of an extended-release formulation of lovastatin in adults with hypercholesterolemia. 11792349 2002 02 21 2013 11 21 0002-9149 89 2 2002 Jan 15 The American journal of cardiology Am. J. Cardiol. Dose response, safety, and efficacy of an extended-release formulation of lovastatin in adults with hypercholesterolemia. 226-9 Crouse John R JR 3rd Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. jcrouse@wfubmc.edu Lukacsko Peter P (...) Niecestro Robert R Friedhoff Lawrence L eng Clinical Trial Journal Article Randomized Controlled Trial United States Am J Cardiol 0207277 0002-9149 0 Anticholesteremic Agents 0 Delayed-Action Preparations 9LHU78OQFD Lovastatin AIM IM Am J Cardiol 2000 Jun 15;89(12):1452 Adult Aged Anticholesteremic Agents administration & dosage therapeutic use Delayed-Action Preparations Dose-Response Relationship, Drug Double-Blind Method Female Humans Hypercholesterolemia drug therapy Lovastatin administration

2002 The American journal of cardiology Controlled trial quality: uncertain

13. Corrigendum: Lovastatin blocks Kv1.3 channel in human T cells: a new mechanism to explain its immunomodulatory properties Full Text available with Trip Pro

Corrigendum: Lovastatin blocks Kv1.3 channel in human T cells: a new mechanism to explain its immunomodulatory properties 26961979 2016 10 08 2045-2322 6 2016 Mar 10 Scientific reports Sci Rep Corrigendum: Lovastatin blocks Kv1.3 channel in human T cells: a new mechanism to explain its immunomodulatory properties. 21655 10.1038/srep21655 Zhao Ning N Dong Qian Q Qian Cheng C Li Sen S Wu Qiong-Feng QF Ding Dan D Li Jing J Wang Bin-Bin BB Guo Ke-Fang KF Xie Jiang-Jiao JJ Cheng Xiang X Liao Yu-Hua

2016 Scientific reports

14. Lovastatin causes FaDu hypopharyngeal carcinoma cell death via AMPK-p63-survivin signaling cascade Full Text available with Trip Pro

Lovastatin causes FaDu hypopharyngeal carcinoma cell death via AMPK-p63-survivin signaling cascade Statins are used widely to lower serum cholesterol and the incidence of cardiovascular diseases. Growing evidence shows that statins also exhibit beneficial effects against cancers. In this study, we investigated the molecular mechanisms involved in lovastatin-induced cell death in Fadu hypopharyngeal carcinoma cells. Lovastatin caused cell cycle arrest and apoptosis in FaDu cells. Lovastatin (...) increased p21(cip/Waf1) level while the survivin level was decreased in the presence of lovastatin. Survivin siRNA reduced cell viability and induced cell apoptosis in FaDu cells. Lovastatin induced phosphorylation of AMP-activated protein kinase (AMPK), p38 mitogen-activated protein kinase (MAPK) and transcription factor p63. Lovastatin also caused p63 acetylation and increased p63 binding to survivin promoter region in FaDu cells. AMPK-p38MAPK signaling blockade abrogated lovastatin-induced p63

2016 Scientific reports

15. Lovastatin Decreases the Expression of CD133 and Influences the Differentiation Potential of Human Embryonic Stem Cells Full Text available with Trip Pro

Lovastatin Decreases the Expression of CD133 and Influences the Differentiation Potential of Human Embryonic Stem Cells The lipophilic statin lovastatin decreases cholesterol synthesis and is a safe and effective treatment for the prevention of cardiovascular diseases. Growing evidence points at antitumor potential of lovastatin. Therefore, understanding the molecular mechanism of lovastatin function in different cell types is critical to effective therapy design. In this study, we investigated (...) the effects of lovastatin on the differentiation potential of human embryonic stem (hES) cells (H9 cell line). Multiparameter flow cytometric assay was used to detect changes in the expression of transcription factors characteristic of hES cells. We found that lovastatin treatment delayed NANOG downregulation during ectodermal and endodermal differentiation. Likewise, expression of ectodermal (SOX1 and OTX2) and endodermal (GATA4 and FOXA2) markers was higher in treated cells. Exposure of hES cells

2016 Stem Cells International

16. Effects of Lovastatin on MDA-MB-231 Breast Cancer Cells: An Antibody Microarray Analysis Full Text available with Trip Pro

Effects of Lovastatin on MDA-MB-231 Breast Cancer Cells: An Antibody Microarray Analysis Despite the tremendous improvement in cancer therapeutics, treatment of late-stage breast cancer remains a challenge for both basic scientists and clinicians. Lovastatin, a natural product derived from Aspergillus terreus or Monascus ruber, has been widely used as cholesterol-lowing drug in the clinic. It also has anti-cancer properties through poorly defined molecular mechanisms. In the present study, we (...) employed a novel antibody microarray technology to investigate the molecular mechanisms through which lovastatin inhibits breast cancer. We found that lovastatin up-regulated 17 proteins and down-regulated 20 proteins in MDA-MB-231 breast cancer cells. These included proteins that modulate apoptosis, cell proliferation, differentiation, signal transduction, epithelial-to-mesenchymal transition and tumor metastasis. Modulation of these pathways may mediate, in part, the inhibitory activity of lovastatin

2016 Journal of Cancer

17. Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPARγ-dependent pathway Full Text available with Trip Pro

Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPARγ-dependent pathway Statins (3-hydroxy-3-methylglutaryl coenzyme A [HMG-CoA] reductase inhibitors) are well-established agents to treat hyperlipidemic states. Experimental and epidemiological evidence further implies an anticancer effect of these substances. This study investigates the mechanism underlying human lung cancer cell death by lovastatin and the role of the prostaglandin (PG)-synthesizing enzyme (...) cyclooxygenase-2 (COX-2) in this process. In A549 and H358 lung carcinoma cells the lipophilic prodrug lovastatin lactone led to a concentration-dependent decrease of viability and induction of DNA fragmentation, whereas its HMG-CoA-inhibitory, ring-open acid form was inactive in this respect. Apoptotic cell death by lovastatin was accompanied by high intracellular levels of the lactone form, by upregulation of COX-2 mRNA and protein, as well as by increased formation of peroxisome proliferator-activated

2016 Oncotarget

18. Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine. (Abstract)

Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine. 8962211 1997 01 21 2013 11 21 0041-1345 28 6 1996 Dec Transplantation proceedings Transplant. Proc. Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine. 3126-8 Kliem V V Abteilung Nephrologie, Medizinische Hochschule, Hannover, Germany. Wanner C C Eisenhauer T T Olbricht C J CJ Doll R R Boddaert M M O'Grady P P Krekler M M Mangold B B Christians U U eng Clinical (...) Trial Comparative Study Journal Article Multicenter Study Randomized Controlled Trial United States Transplant Proc 0243532 0041-1345 0 Anticholesteremic Agents 0 Cholesterol, HDL 0 Cholesterol, LDL 0 Cholesterol, VLDL 0 Immunosuppressive Agents 0 Triglycerides 83HN0GTJ6D Cyclosporine 97C5T2UQ7J Cholesterol 9LHU78OQFD Lovastatin KXO2KT9N0G Pravastatin IM Adult Aged Anticholesteremic Agents pharmacokinetics therapeutic use Cholesterol blood Cholesterol, HDL blood Cholesterol, LDL blood Cholesterol

1997 Transplantation proceedings Controlled trial quality: uncertain

19. Long-term experience with lovastatin treatment in patients with coronary heart disease and hyperlipoproteinaemia type II. (Abstract)

Long-term experience with lovastatin treatment in patients with coronary heart disease and hyperlipoproteinaemia type II. 1644101 1992 09 10 2013 11 21 0195-668X 13 Suppl B 1992 Jul European heart journal Eur. Heart J. Long-term experience with lovastatin treatment in patients with coronary heart disease and hyperlipoproteinaemia type II. 7-10 Zhukova I I Institute of Clinical Cardiology, USSR Cardiology Research Center, Moscow. Yurenev A A Kukharchuk V V Pomerantsev E E Titov V V Shabalkin B B (...) Martinov A A eng Clinical Trial Journal Article Randomized Controlled Trial England Eur Heart J 8006263 0195-668X 0 Lipids 9LHU78OQFD Lovastatin IM Adult Aged Angina Pectoris blood drug therapy Coronary Artery Disease blood drug therapy Coronary Disease blood drug therapy Double-Blind Method Exercise Test drug effects Female Humans Hyperlipoproteinemia Type II blood drug therapy Lipids blood Lovastatin therapeutic use Male Middle Aged 1992 7 1 1992 7 1 0 1 1992 7 1 0 0 ppublish 1644101

1992 European Heart Journal Controlled trial quality: uncertain

20. The human lens after 48 weeks of treatment with lovastatin. (Abstract)

The human lens after 48 weeks of treatment with lovastatin. 2385275 1990 09 20 2013 11 21 0028-4793 323 10 1990 Sep 06 The New England journal of medicine N. Engl. J. Med. The human lens after 48 weeks of treatment with lovastatin. 683-4 Laties A M AM Keates E U EU Taylor H R HR Chremos A N AN Shear C L CL Lippa E A EA Gould A L AL Hurley D P DP eng Clinical Trial Letter Randomized Controlled Trial United States N Engl J Med 0255562 0028-4793 9LHU78OQFD Lovastatin AIM IM Adult Aged Cataract (...) chemically induced Female Humans Lens, Crystalline drug effects Lovastatin adverse effects Male Middle Aged Time Factors Visual Acuity drug effects 1990 9 6 1990 9 6 0 1 1990 9 6 0 0 ppublish 2385275 10.1056/NEJM199009063231015

1990 The New England journal of medicine Controlled trial quality: uncertain